Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-naive Human Immunodeficiency Virus Controllers

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2008 Nov 7

PMID 18987151

Citations 73

Authors

Madhumita Mahalanabis

Pushpa Jayaraman

Toshiyuki Miura

Florencia Pereyra

E Michael Chester

Barbra Richardson

Bruce Walker

Nancy L Haigwood

Affiliations

Soon will be listed here.

Abstract

We assessed differences in the character and specificity of autologous neutralizing antibodies (ANAbs) against individual viral variants of the quasispecies in a cohort of drug-naïve subjects with long-term controlled human immunodeficiency virus type 1 (HIV-1) infection and moderate levels of broad heterologous neutralizing antibodies (HNAb). Functional plasma virus showed continuous env evolution despite a short time frame and low levels of viral replication. Neutralization-sensitive variants dominated in subjects with intermittent viral blips, while neutralization-resistant variants predominated in elite controllers. By sequence analysis of this panel of autologous variants with various sensitivities to neutralization, we identified more than 30 residues in envelope proteins (Env) associated with resistance or sensitivity to ANAbs. The appearance of new sensitive variants is consistent with a model of continuous selection and turnover. Strong ANAb responses directed against autologous Env variants are present in long-term chronically infected individuals, suggesting a role for these responses in contributing to the durable control of HIV replication.

Citing Articles

Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral Replication.

Lee S, Sondgeroth A, Xu Y, Warren J, Zhou S, Gilleece M Open Forum Infect Dis. 2024; 11(5):ofae212.

PMID: 38756763 PMC: 11097118. DOI: 10.1093/ofid/ofae212.

Comparison of the Biological Basis for Non-HIV Transmission to HIV-Exposed Seronegative Individuals, Disease Non-Progression in HIV Long-Term Non-Progressors and Elite Controllers.

Hokello J, Tyagi P, Dimri S, Sharma A, Tyagi M Viruses. 2023; 15(6).

PMID: 37376660 PMC: 10301403. DOI: 10.3390/v15061362.

Ongoing HIV-1 evolution and reservoir reseeding in two elite controllers with genetically diverse peripheral proviral quasispecies.

de Azevedo S, Cortes F, Villela L, Hoagland B, Grinsztejn B, Veloso V Mem Inst Oswaldo Cruz. 2023; 118:e230066.

PMID: 37283423 PMC: 10292822. DOI: 10.1590/0074-02760230066.

Characterizing the Relationship Between Neutralization Sensitivity and Gene Diversity During ART Suppression.

Wilson A, Shakhtour L, Ward A, Ren Y, Recarey M, Stevenson E Front Immunol. 2021; 12:710327.

PMID: 34603284 PMC: 8479156. DOI: 10.3389/fimmu.2021.710327.

Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH.

Tomescu C, Kroll K, Colon K, Papasavvas E, Frank I, Tebas P Eur J Immunol. 2021; 51(8):2051-2061.

PMID: 34086344 PMC: 8338900. DOI: 10.1002/eji.202149188.

References

Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

Cao Y, Qin L, Zhang L, Safrit J, Ho D . Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995; 332(4):201-8. DOI: 10.1056/NEJM199501263320401. View

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

Richman D, Wrin T, Little S, Petropoulos C . Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003; 100(7):4144-9. PMC: 153062. DOI: 10.1073/pnas.0630530100. View

Moir S, Ogwaro K, Malaspina A, Vasquez J, Donoghue E, Hallahan C . Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A. 2003; 100(10):6057-62. PMC: 156325. DOI: 10.1073/pnas.0730819100. View

Chenna R, Sugawara H, Koike T, Lopez R, Gibson T, Higgins D . Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31(13):3497-500. PMC: 168907. DOI: 10.1093/nar/gkg500. View

Mongkolsapaya J, Dejnirattisai W, Xu X, Vasanawathana S, Tangthawornchaikul N, Chairunsri A . Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003; 9(7):921-7. DOI: 10.1038/nm887. View

Kumar S, Tamura K, Nei M . MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 2004; 5(2):150-63. DOI: 10.1093/bib/5.2.150. View

Montefiori D, Pantaleo G, Fink L, Zhou J, Zhou J, Bilska M . Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996; 173(1):60-7. DOI: 10.1093/infdis/173.1.60. View

10.

Scarlatti G, Leitner T, Hodara V, Jansson M, Karlsson A, Wahlberg J . Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS. Immunol Lett. 1996; 51(1-2):23-8. DOI: 10.1016/0165-2478(96)02550-3. View

11.

Cole K, Rowles J, Jagerski B, Murphey-Corb M, Unangst T, Clements J . Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol. 1997; 71(7):5069-79. PMC: 191740. DOI: 10.1128/JVI.71.7.5069-5079.1997. View

12.

Delwart E, Gordon C . Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods. 1997; 12(4):348-54. DOI: 10.1006/meth.1997.0489. View

13.

Delwart E, Pan H, Sheppard H, Wolpert D, Neumann A, Korber B . Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol. 1997; 71(10):7498-508. PMC: 192096. DOI: 10.1128/JVI.71.10.7498-7508.1997. View

14.

Chackerian B, Rudensey L, Overbaugh J . Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol. 1997; 71(10):7719-27. PMC: 192123. DOI: 10.1128/JVI.71.10.7719-7727.1997. View

15.

Pilgrim A, Pantaleo G, Cohen O, Fink L, Zhou J, Zhou J . Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997; 176(4):924-32. DOI: 10.1086/516508. View

16.

Zhang Y, Fracasso C, Fiore J, Bjorndal A, Angarano G, Gringeri A . Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997; 176(5):1180-7. DOI: 10.1086/514111. View

17.

Thompson J, Gibson T, Plewniak F, Jeanmougin F, Higgins D . The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1998; 25(24):4876-82. PMC: 147148. DOI: 10.1093/nar/25.24.4876. View

18.

Klenerman P, Zinkernagel R . Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature. 1998; 394(6692):482-5. DOI: 10.1038/28860. View

19.

Bradney A, Scheer S, Crawford J, Buchbinder S, Montefiori D . Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis. 1999; 179(5):1264-7. DOI: 10.1086/314711. View

20.

Cecilia D, Kleeberger C, Munoz A, Giorgi J, Zolla-Pazner S . A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis. 1999; 179(6):1365-74. DOI: 10.1086/314773. View